ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements with these filters
Sai Life Sciences Limited has announced the allotment of equity shares under its ESOP scheme. This allotment increases the company's paid-up share capital.
Sai Life Sciences allotted 24,000 shares upon exercise of ESOP 2008 options at ₹188.90 per share. This issuance increases the company's paid-up equity share capital.
Sai Life Sciences summarised proceedings of its 27th AGM held 17 Sep 2026. Shareholders adopted FY25-26 financials and re-appointed MD Krishnamraju Kanumuri.
Sai Life Sciences Limited allotted 80,600 equity shares under its ESOP/ESPS scheme. This increased the company's total paid-up share capital to ₹21.24 Crore.
Sai Life Sciences Limited allotted 80,600 equity shares following the exercise of options under its 2008 and 2018 ESOP plans. The total paid-up capital increased to ₹21.24 Crore.
Sai Life Sciences submitted its Business Responsibility and Sustainability Report (BRSR) and ESG Databook for the financial year 2025-26, as required by regulatory norms.
Sai Life Sciences has filed its Integrated Annual Report for FY 2025-26, including the notice for the 27th AGM scheduled on September 17, 2026.
Sai Life Sciences Limited scheduled its 27th Annual General Meeting for September 17, 2026. The company set September 10, 2026, as the cut-off date for e-voting.
Sai Life Sciences Limited filed its Monitoring Agency Report for the quarter ended 30 June 2026 regarding its IPO proceeds utilization.
Sai Life Sciences delivered strong Q1FY27 performance with revenue of ₹554 Cr, up 12% YoY, and PAT of ₹73 Cr, up 22% YoY, driven by growth in CRO and CDMO segments.
Sai Life Sciences Limited allotted 18,700 equity shares under its ESOP/ESPS scheme. This issuance increases the total paid-up share capital of the company.
Sai Life Sciences allotted 18,700 equity shares under its Employee Stock Option Plan 2008. The exercise of these options realized Rs. 0.35 Crore for the company.
Sai Life Sciences reported Q1 FY27 revenue of ₹554 crore and PAT of ₹73 crore. It also operationalized a new 100,000 sq. ft. R&D facility.
Sai Life Science Ltd reported revenue from operations of ₹554.3 Cr (+11.7% YoY) and net profit of ₹73.3 Cr (+21.2% YoY) for Q1 FY27.
Sai Life Sciences Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per regulatory requirements.
Sai Life Sciences allotted 8,900 equity shares under its ESOP/ESPS scheme. This increases the total paid-up share capital to 21,22,94,916 shares.
Sai Life Sciences Limited allotted 8,900 equity shares under its ESOP 2008 scheme. The company realized Rs 0.17 Crore from the exercise of these options.
Sai Life Sciences has scheduled a board meeting on 06 August 2026 to consider financial results for Q2 2026. Trading window remains closed till 08 August 2026.
Sai Life Sciences reported robust FY26 performance with 29% revenue growth and 109% PAT growth, driven by deepening engagement with 19 of top 25 global pharma companies.
Sai Life Sciences delivered strong FY26 performance with 29% revenue growth and 56% EBITDA growth, driven by expansion in CDMO and CRO segments and improved operating leverage.
Sai Life Sciences disclosed certified Key Performance Indicators for fiscal years 2022-2026. The metrics provide detailed visibility into revenue growth, margins, and operational efficiency.
Sai Life Sciences reported FY26 revenue of ₹2,192 Crore, representing 29% growth. Net profit doubled to ₹355 Crore, driven by deep engagement with large pharma customers.
Sai Life Science Ltd reported revenue from operations of ₹602.1 Cr (+3.9% YoY) and net profit of ₹104.2 Cr (+18.0% YoY) for Q4 FY26.
Sai Life Sciences approved its FY2026 audited financial results. Consolidated annual revenue reached ₹21,924.92 million, reflecting significant year-on-year growth and strong operational performance.
Sai Life Sciences announced its Bidar campus transitioned to 100% renewable energy usage. This milestone marks the first Indian CRDMO site to achieve full renewable power.
Sai Life Sciences received a ₹32.86 Crore GST demand order (including interest and penalties) for FY 2021-22 from the Karnataka tax authorities. The demand relates to alleged excess Input Tax Credit availment. The company plans to appeal the order at the Tribunal level and does not expect any material financial impact.
Sai Life Sciences Limited allotted 2,44,281 equity shares upon the exercise of options under its ESOP 2008 and MESOP 2018 plans. The company realized ₹3.38 Crore from this exercise. Following this allotment, the total issued share capital increased to 21,20,23,515 equity shares.
Sai Life Sciences Limited has scheduled a board meeting on May 14, 2026, to approve audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company also confirmed that its trading window for designated persons has been closed from April 1, 2026, until May 16, 2026.